# An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

> **NCT02917993** · PHASE1,PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 59 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Itacitinib
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT02917993
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-20
- **Primary completion:** 2025-12-24
- **Final completion:** 2025-12-24
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02917993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02917993, "An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02917993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*